

Press Release

SYN|thesis med chem Pty to provide medicinal and computational chemistry services to Cellzome

Melbourne, Australia, Cambridge, United Kingdom and Heidelberg, Germany, 8th June 2010 - SYN|thesis Med Chem Pty Ltd. and its affiliate, Qubist Molecular Design, announced today that they have signed an agreement with Cellzome to provide contract medicinal chemistry services. Synthetic and medicinal chemistry will be carried out at SYN|thesis med chem's facility in Shanghai, People's Republic of China and computational chemistry by Qubist in Melbourne, Australia.

Andrew Ratcliffe, Director of Chemistry at Cellzome, commented "SYN|thesis not only offers us cost effective chemistry resources but also brings a wealth of experience in drug discovery which we can leverage in our own programmes". Andrew Wilks, Executive Chairman of SYN|thesis med chem said, "We are very much looking forward to working with Cellzome. Their pioneering approach to drug discovery based upon their chemical proteomics platform, coupled with our own computational and medicinal chemistry expertise should make an exciting and productive combination."

- ends -

About SYN|thesis Med Chem Pty Ltd

SYN|thesis med chem Pty Ltd is a leading medicinal chemistry Contract Research Organisation (CRO) that provides important research tools, reagents and contract research services to facilitate and accelerate the drug discovery process. Based in Melbourne, Australia and Shanghai, PRC, our customers include academic research institutions, pharmaceutical companies and biotechnology companies around the world all of which participate in the discovery of new drugs. As well as providing comprehensive medicinal chemistry services, SYN|thesis provides computational chemistry services through its subsidiary, Qubist Molecular Design. Qubist employs a quantum mechanical approach to delivering improved *in silico* screening and drug design.

About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases. Our pipeline of small-molecule therapeutics is driven by *Kinobeads*[™], a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called *Episphere*[™] to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Cellzome has two strategic alliances with GSK to discover and develop drugs to treat inflammatory diseases, the first in the field of kinase-targeted therapeutics and the second in the field of epigenetics.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: www.cellzome.com.